Pathios Therapeutics

Pathios Therapeutics is an early-stage drug discovery company established in 2017 by experienced pharmaceutical industry professionals and biotech entrepreneurs. Based in Oxford, UK, the company focuses on pioneering a novel macrophage conditioning approach to deliver breakthrough cancer therapies. Pathios leverages a deep understanding of the biology of tumour-associated macrophages (TAMs) to identify small-molecule modulators of GPR65 with potential applications across various cancers. Additionally, the company explores targeting GPR65 for the treatment of other serious diseases.

Pathios' scientific approach includes mapping the signaling of key GPCRs on immune cells based on human genetic insights, transcriptomics, and cellular immunology. Identified as a key innate immune checkpoint on TAMs, GPR65 serves as the focal point for the development of novel therapeutic agents. The company collaborates with scientific leaders and strategic external partners to conduct efficient drug discovery activities, capitalizing on the latest advances in GPCR drug discovery.

The most recent milestone for Pathios Therapeutics is the €23.40M Series B investment received on 18 April 2024, with participation from prominent investors including Brandon Capital, Bristol Myers Squibb, and Canaan. This funding is poised to propel the company's innovative approach to cancer therapy and holds promise for addressing unmet medical needs in various disease areas within the biotechnology and healthcare industries.